Addex Therapeutics (ADXN) EBIAT (2022 - 2025)
Historic EBIAT for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$2.0 million.
- Addex Therapeutics' EBIAT fell 1182.67% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1638.2 billion, marking a year-over-year increase of 5368.24%. This contributed to the annual value of $8.0 million for FY2024, which is 16823.63% up from last year.
- As of Q3 2025, Addex Therapeutics' EBIAT stood at -$2.0 million, which was down 1182.67% from -$2.4 million recorded in Q2 2025.
- In the past 5 years, Addex Therapeutics' EBIAT ranged from a high of -$579883.9 in Q2 2023 and a low of -$3536.9 billion during Q1 2024
- Over the past 4 years, Addex Therapeutics' median EBIAT value was -$2.8 million (recorded in 2023), while the average stood at -$345.0 billion.
- Its EBIAT has fluctuated over the past 5 years, first soared by 9226.59% in 2023, then crashed by 13590096289.68% in 2024.
- Addex Therapeutics' EBIAT (Quarter) stood at -$21.6 million in 2022, then surged by 86.95% to -$2.8 million in 2023, then plummeted by 98.83% to -$5.6 million in 2024, then soared by 64.82% to -$2.0 million in 2025.
- Its last three reported values are -$2.0 million in Q3 2025, -$2.4 million for Q2 2025, and -$1638.2 billion during Q1 2025.